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PURPOSE
Solid crystal suspension (SCS) is an emerging technique
for dissolution enhancement, in which the crystalline drug
is suspended in crystalline excipient. Development of
SCS of carbamazepine (CBM) with carriers mannitol and
xylitol via a solvent free Hot-melt extrusion (HME)
techniques to improve the dissolution.
OBJECTIVES
The main aim of current research is to investigate the
development of solid crystal suspensions (SCS) of
carbamazepine (CBM) to improve dissolution by Hot-melt
extrusion (HME) techniques. The hydrophilic crystalline
carriers xylitol (XYL) and mannitol (MAN) were
investigated to assess the formation of SCSs.
METHOD
HME processing
The physical mixtures of CBM with varied drug loads (10% & 20%) and either of the carriers XYL or MAN were
prepared by blending for 10 min at 20 rpm in V-blender (GlobePharma, MaxiblendTM). The extrusion process was
performed using a counter-rotating mini extruder (Haake MiniLab II, Thermo Electron, USA) at a screw speed of 50 rpm
and at a processing temperature of 96°C & 170°C for XYL and MAN, respectively. The collected extrudates were
cooled at room temperature, milled, sieved and stored in a desiccator until further evaluations. All the prepared
formulations (CBM-MAN and CBM-XYL) were characterized by DSC and FTIR.
Differential scanning calorimetry (DSC)
The milled extrudates were characterized using differential scanning calorimetry (TA Instruments) to determine
crystalline state of the CBM.
Fourier-transform infrared spectroscopy (FTIR)
FTIR was performed to investigate the solid-state intermolecular interactions between CBM and carrier using Agilent
Cary 660 FTIR Spectrometer (Agilent Technologies).
In-vitro dissolution
In-vitro dissolution studies of pure CBM and prepared SCS formulation was performed in 900 mL of 1% SLS in water
for 60 min using USP apparatus II (SR8-plus, Hanson) at an agitation speed of 50 RPM and the drug release was
evaluated using a UV–Vis spectrophotometer (Genesys 180, Thermoscientific) at a wavelength of 288 nm.
RESULTS
Figure 1. DSC thermograms of CBM, MAN, XYL, and SCS formulations
Figure 2. FTIR spectra of CBM, MAN, XYL, and SCS formulations
Figure 3. Dissolution of CBM, MAN, XYL, and SCS formulations in 1% SLS in 
water
CONCLUSION
CBM-MAN and CBM-XYL solid crystal
suspensions were successfully prepared by
hydrophilic carriers using HME. Studies
revealed existence of formulations in crystalline
form with no interactions. Furthermore, SCS
was identified as a promising approach for
enhancing solubility and dissolution of poorly
soluble drugs.
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Formulation CBM MAN XYL
CBM-MAN (10-90) 10 90 -
CBM-MAN (20-80) 20 80 -
CBM-XYL (10-90) 10 - 90
CBM-XYL (20-80) 20 - 80
Table 1. SCS formulations composition 
